AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Jonah Keri
After hitting a high of 19.45 on June 17, Endo Pharmaceuticals has corrected for six weeks. The stock may be forming the early stages of a base. As discussed in IBD WebLink on Thursday, don't cheat on a stock by buying before the breakout. Endo's trading below its 50-day moving average, 20% off its high.
The maker of acetaminophen-based painkiller Percocet and aspirin-based painkiller Percodan has posted year-over-year revenue growth of 41% to 127% in the last six quarters.
Profit has grown in triple digits during that time, except for last quarter, when ...